Jackisch, Christian http://orcid.org/0000-0001-8537-3743
Anastasiadou, Louiza
Aulmann, Sebastian
Argyriadis, Athanasios
Möbus, Volker
Solbach, Christine
Baier, Peter
Giesecke, Dagmar
Ackermann, Sven
Schulmeyer, Elke
Gabriel, Boris
Mosch, Dietrich
Buchen, Stephanie
Krapfl, Eckart
Hurst, Ursula
Vescia, Mario
Tesch, Hans
Thill, Marc
Funding for this research was provided by:
Exact Sciences
Article History
Received: 20 October 2023
Accepted: 22 May 2024
First Online: 14 June 2024
Declarations
:
: Financial interests: C. Jackisch reports participating in advisory boards for Roche, AstraZeneca, Pfizer, Celgene, Lilly, and Exact Sciences; being a speaker and chairman for educational events for Roche, AstraZeneca, Pfizer, Celgene, Exact Sciences, Lilly, and Pierre-Fabré; and receiving research funding from Novartis, Exact Sciences, and Roche. M. Thill reports participating in advisory boards for Agendia, Amgen, AstraZeneca, Aurikamed, Becton/Dickinson, Biom ‘Up, ClearCut, Clovis, Daiichi Sankyo, Eisai, Exact Sciences, Gilead Science, Grünenthal, GSK, Lilly, MSD, Norgine, Neodynamics, Novartis, Onkowissen, Organon, Pfizer, pfm Medical, Pierre-Fabre, Roche, RTI Surgical, Seagen, Sirius Pintuition, and Sysmex; receiving manuscript support from Amgen, ClearCut, Clovis, pfm medical, Roche, and Servier; receiving travel support from Amgen, Art Tempi, AstraZeneca, Clearcut, Clovis, Connect Medica, Daiichi Sankyo, Eisai, Exact Sciences, Hexal, I-Med-Institute, Lilly, MCI, Medtronic, MSD, Norgine, Novartis, Pfizer, pfm Medical, Roche, RTI Surgical, and Seagen; congress support from Amgen, AstraZeneca, Celgene, Daiichi Sanyko, Hexal, Neodynamics, Novartis, Pfizer, and Roche; lecture honoraria from Amgen, Art Tempi, AstraZeneca, Clovis, Connect Medica, Eisai, Exact Sciences, Gilead Science, Hexal, I-Med-Institute, Jörg Eickeler, Lilly, MCI, Medtronic, MSD, Novartis, Omniamed, Onkowissen, Pfizer, pfm Medical, Roche, RTI Surgical, Seagen, Sysmex, Vifor, and Viatris; and trial funding from Endomag, and Exact Sciences. The remaining authors declare no competing financial or non-financial interests.
: The study protocol was approved by the responsible Ethics Committee at the Board of Physicians in Hessen (study number FF48/2015) and informed consent was obtained from all participating patients. The study has been carried out in accordance with the Declaration of Helsinki.